Simplex Trading’s KalVista Pharmaceuticals KALV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-15,400
| Closed | -$310K | – | 9807 |
|
|
2026
Q1 | $310K | Buy |
+15,400
| New | +$248K | ﹤0.01% | 3792 |
|
|
2025
Q4 | – | Sell |
-600
| Closed | -$7K | – | 9316 |
|
|
2025
Q3 | $7K | Sell |
600
-1,400
| -70% | -$19.3K | ﹤0.01% | 8112 |
|
|
2025
Q2 | $22K | Buy |
+2,000
| New | +$24.5K | ﹤0.01% | 6695 |
|
|
2025
Q1 | – | Sell |
-126,800
| Closed | -$1.07M | – | 9066 |
|
|
2024
Q4 | $1.07M | Buy |
126,800
+125,600
| +10,467% | +$1.3M | ﹤0.01% | 2762 |
|
|
2024
Q3 | $13K | Sell |
1,200
-4,300
| -78% | -$54.1K | ﹤0.01% | 7003 |
|
|
2024
Q2 | $64K | Sell |
5,500
-7,100
| -56% | -$82.9K | ﹤0.01% | 5820 |
|
|
2024
Q1 | $149K | Sell |
12,600
-400,200
| -97% | -$5.34M | ﹤0.01% | 5160 |
|
|
2023
Q4 | $5.06M | Buy |
412,800
+408,400
| +9,282% | +$3.72M | ﹤0.01% | 1541 |
|
|
2023
Q3 | $42K | Buy |
+4,400
| New | +$45K | ﹤0.01% | 5963 |
|
|
2021
Q4 | – | Sell |
-8,500
| Closed | -$208K | – | 10935 |
|
|
2021
Q3 | $208K | Hold |
8,500
| – | – | ﹤0.01% | 5534 |
|
|
2021
Q2 | $203K | Buy |
8,500
+8,454
| +18,378% | +$221K | ﹤0.01% | 5659 |
|
|
2021
Q1 | $118K | Buy |
46
+28
| +156% | +$736 | ﹤0.01% | 5508 |
|
|
2020
Q4 | $34K | Buy |
+18
| New | +$309 | ﹤0.01% | 6560 |
|
Other funds holding KALV
Simplex Trading's KALV Position: Q3 2025 in Review
Simplex Trading sold out of KalVista Pharmaceuticals (KALV) in Q3 2025, closing a stake of 3,543 shares — an estimated $49K sold.
Simplex Trading first reported a position in KALV in Q4 2020 and held it in 14 quarters. The position peaked at $297K in Q4 2024. 145 funds tracked by Wall St. Rank hold KALV as of Q3 2025.
- Simplex Trading reported no remaining KalVista Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
- Simplex Trading sold 3,543 KalVista Pharmaceuticals shares in Q3 2025, an estimated $49K.
- Simplex Trading first reported a position in KalVista Pharmaceuticals in Q4 2020 and held it in 14 quarters.
- Simplex Trading's KalVista Pharmaceuticals position peaked at $297K in Q4 2024.
- 145 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q3 2025.
Based on Simplex Trading's 13F filing for Q3 2025, filed 12 Nov 2025.